Search the Newsreel

Journey Medical Corp (DERM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Journey Medical Corp (DERM), detailing its current valuation score, market capitalization, and P/E ratio. It notes that the company ranks 47th out of 155 in the Pharmaceuticals industry based on its valuation score. The report also highlights …

Journey Medical Corp (DERM) Financial Health: Profitability & Balance Sheet Analysis

Journey Medical Corp (DERM) has a current financial score of 7.65, placing it 107th in the Pharmaceuticals industry. The company shows stable financial status and high operating efficiency, with a recent quarterly revenue of $15.96 million, marking a 21.48% year-over-year increase, and a net …

DERM stock holds focus on Journey Medical Corp results

This article focuses on DERM stock, which is the Nasdaq-listed ticker for Journey Medical Corp (ISIN US48113J1007). It confirms the company's identity and listing context as a pharmaceutical company specializing in dermatology products. Due to the absence of live market data, the article emphasizes …

Galderma Group AG (GDERF) Half Year 2026 Earnings Call Highlights: Record Sales and Strategic ...

This article first appeared on GuruFocus. Release Date: July 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Galderma Group AG (GDERF) delivered record net sales of USD 3.1 billion in the first …

Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, July 23, 2026--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD …

Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region

Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an …

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics' investigational oral drug VDPHL01 for female pattern hair loss showed positive results in a Phase 2 trial, demonstrating consistent hair growth and early activity within two months. The treatment was well-tolerated, with participants experiencing clinically meaningful improvements in hair count and coverage. The …

Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW

This article provides the "Price to earnings forward" data for Dermata Therapeutics, Inc. (NASDAQ:DRMAW). It indicates that the market is currently closed, with no trades, and the data is sourced from ICE Data Services and FactSet Research Systems Inc.

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics, Incorporated announced the presentation of data from a subgroup analysis of its Phase 2/3 study '302' for VDPHL01 in male patients with pattern hair loss. The data were shared at the 2026 American Academy of Dermatology Innovation Academy, detailing the efficacy and safety …

Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data

(RTTNews) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks. Positive data readouts spanned multiple therapeutic areas, including pulmonary arterial hypertension, weight loss, pattern …

Veradermics Is Maintained at Buy by Citigroup

Citigroup has maintained its "Buy" rating on Veradermics. The article indicates a positive outlook from the analytical firm regarding the company.

Veradermics (NYSE:MANE) Shares Gap Up on Analyst Upgrade

Veradermics (NYSE:MANE) shares gapped up significantly after Needham & Company raised its price target and reaffirmed a buy rating. This positive movement was further fueled by encouraging Phase 2 data for the company's oral hair-loss drug, VDPHL01, showing improved outcomes for women with pattern …

Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

Veradermics' experimental baldness drug, VDPHL01, an extended-release minoxidil, showed promising Phase 2 results in women with mild-to-moderate pattern hair loss, exceeding investor expectations. The drug led to a mean increase of about 23 hairs per square centimeter after six months, with most participants and …

Veradermics’ oral treatment for female pattern hair loss delivers positive study results

Veradermics announced positive topline results from its Phase 2 clinical trial (Study ‘207’) for VDPHL01, an oral minoxidil formulation for female pattern hair loss. The treatment showed fast onset of hair growth, with a high percentage of patients reporting improvement by Month 6. Veradermics …

MANE Q1 2026 Earnings: Steeper-than-expected Loss Sends Shares Down 11.5% - Pretax Income Report

MANE Stock Draws Traders As Volatility And Cash Pile Stand Out

Veradermics Incorporated (MANE) stock has seen a significant 12.28% increase due to positive dermatology trial results, attracting active traders. Despite recent pullbacks from highs near $130, the company boasts a strong cash position of $168 million with minimal liabilities, providing a substantial runway for …

Veradermics jumps after mid-stage trial data for lead drug in female pattern hair loss

Shares of Veradermics (MANE) rose significantly after the company released positive topline data from a Phase 2 study for its lead asset, VDPHL01. This data pertains to the treatment of female pattern hair loss and validates the design of an upcoming registrational trial. The …

Veradermics (NYSE: MANE) posts strong VDPHL01 Phase 2 female data

Veradermics, Inc. reported positive Phase 2 data for VDPHL01, an extended-release oral minoxidil tablet, in women with mild-to-moderate pattern hair loss. The study showed significant hair growth and high patient-reported improvement with good tolerability, positioning VDPHL01 as a potential first FDA-approved oral treatment for …

Veradermics Reports Positive Phase 2 Results for Oral Non-Hormonal Hair Loss Drug in Women

Veradermics has announced positive Phase 2 results for VDPHL01, an oral non-hormonal hair loss drug for women. The study showed significant improvement in hair growth at 24 weeks, supporting its advancement to Phase 3. If approved, VDPHL01 would be the first FDA-approved oral non-hormonal …

Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too

Veradermics has announced positive topline results from a Phase 2 study of its oral minoxidil formulation, VDPHL01, for female pattern hair loss. The drug demonstrated a "potentially differentiated clinical profile" with swift onset, consistent patient responses, and significant hair count increases. Analysts are optimistic …

Up to 90% of women reported better hair coverage by Month 6

Veradermics announced positive Phase 2 clinical trial results for its oral VDPHL01, an extended-release minoxidil formulation, in female pattern hair loss. The study showed rapid onset of hair growth, with up to 90% of participants reporting improved hair coverage by Month 6, and a …

Veradermics shares climb 9% after encouraging female hair loss trial results (MANE)

Veradermics shares rose 9% following positive Phase 2 clinical trial results for VDPHL01, an oral treatment for female pattern hair loss. The study showed significant improvement in hair count and a favorable safety profile. The company anticipates further trial results later in 2026 and …

B.Riley initiates Veradermics stock coverage with Buy on hair loss drug

B.Riley has initiated coverage on Veradermics Inc. (NYSE:MANE) with a Buy rating and a price target of $170.00, driven by excitement over the company's lead hair loss drug candidate, VDPHL01. This drug is an extended-release oral minoxidil aiming to be the first FDA-approved oral …

Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors

DERM Forecast — Price Target — Prediction for 2027

Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch

Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise

Journey Medical Corporation Q1 2026 Earnings Call Summary

Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks

Journey Medical (DERM) Losses Narrow In Q4 EPS Result Tests Bullish Profitability Narrative

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Dermata Therapeutics Strategically Pivots with New Skincare Launch

Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25